PMID- 12042703
OWN - NLM
STAT- MEDLINE
DCOM- 20021209
LR  - 20191106
IS  - 1065-6251 (Print)
IS  - 1065-6251 (Linking)
VI  - 9
IP  - 4
DP  - 2002 Jul
TI  - Role of peroxisome proliferator-activated receptor-gamma in hematologic 
      malignancies.
PG  - 294-302
AB  - Members of the nuclear receptor superfamily, including retinoic acid receptors 
      (RARs), retinoid X receptors (RXRs), and vitamin D receptors (VDRs), are 
      transcription factors that control many important cellular functions, and their 
      ligands are widely used in several clinical indications. The latest family member 
      is the peroxisome proliferator-activated receptor-gamma (PPARgamma), which is 
      highly expressed in normal monocytes, different leukemias, and epithelial 
      malignancies. PPARgamma ligands have been developed and signal differentiation, 
      growth arrest, and apoptosis. PPARgamma forms heterodimers with RXR, and ligation 
      of both receptors is required for maximal signaling. PPARgamma signaling, its 
      expression in hematologic malignancies, and role in differentiation are 
      discussed. Interactions of PPARgamma with X-RARalpha, protein kinase R (PKR), 
      PTEN, and mitogen-activated protein kinase (MAPK) have been described. PPARgamma 
      ligands have been developed for the management of diabetes, but new and more 
      potent ligands, including triterpenoids, are being investigated as therapeutic 
      agents for epithelial and hematologic malignancies.
FAU - Konopleva, Marina
AU  - Konopleva M
AD  - Department of Blood and Marrow Transplantation, Section of Molecular Hematology 
      and Therapy, University of Texas M. D. Anderson Cancer Center, Houston, Texas 
      77030, USA.
FAU - Andreeff, Michael
AU  - Andreeff M
LA  - eng
GR  - CA16672/CA/NCI NIH HHS/United States
GR  - P01 CA55164/CA/NCI NIH HHS/United States
GR  - R01 CA89346/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Curr Opin Hematol
JT  - Current opinion in hematology
JID - 9430802
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Animals
MH  - DNA-Binding Proteins/*physiology
MH  - Hematologic Neoplasms/*metabolism/pathology
MH  - Humans
MH  - Receptors, Cytoplasmic and Nuclear/*physiology
MH  - Transcription Factors/*physiology
RF  - 72
EDAT- 2002/06/04 10:00
MHDA- 2002/12/10 04:00
CRDT- 2002/06/04 10:00
PHST- 2002/06/04 10:00 [pubmed]
PHST- 2002/12/10 04:00 [medline]
PHST- 2002/06/04 10:00 [entrez]
AID - 10.1097/00062752-200207000-00006 [doi]
PST - ppublish
SO  - Curr Opin Hematol. 2002 Jul;9(4):294-302. doi: 10.1097/00062752-200207000-00006.